Hostname: page-component-745bb68f8f-cphqk Total loading time: 0 Render date: 2025-01-13T09:05:27.709Z Has data issue: false hasContentIssue false
  • English
  • Français

Neuroleptic Malignant Syndrome with Trifluperidol

Published online by Cambridge University Press:  02 January 2018

S. P. Singh ,
C. Giridhar  and
A. Avasthi
S. P. Singh*
Affiliation:
Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh 160 012, India
C. Giridhar
Affiliation:
Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh 160 012, India
A. Avasthi
Affiliation:
Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh 160 012, India
*
∗Correspondence
Get access Rights & Permissions [Opens in a new window]

Abstract

In a case of NMS subsequent to administration of trifluperidol to a young man, the patient responded remarkably quickly to bromocriptine. The authors point out the deficiencies in the diagnostic criteria, which need further refinement for a better understanding of the syndrome.

Type
Brief Reports
Information
The British Journal of Psychiatry , Volume 155 , Issue 4 , October 1989 , pp. 561 - 563
Copyright
Copyright © Royal College of Psychiatrists 1989 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Caroff, N. (1980) The neuroleptic malignant syndrome. Journal of Clinical Psychology, 41, 79–83.Google Scholar
Goulun, M., de Rohan Chabot, P., Elkhaart, D., et al (1983) Beneficial effects of dantrolene in the treatment of neurolepetic malignant syndrome: a report of two cases. Neurology, 33, 516–518.Google Scholar
Guze, G. H. & Baxter, L. R. J. (1985). Neuroleptic malignant syndrome. New England Journal of Medicine, 313, 163–166.Google Scholar
Levenson, J. L. (1985) Neuroleptic malignant syndrome. American Journal of Psychiatry, 142, 1137–1145.Google Scholar
McCarthy, A., Bourke, S., Fahy, J., et al (1988) Fatal recurrence of neuroleptic malignant syndrome. British Journal of Psychiatry, 152, 558–559.Google Scholar
Misiazek, J. J. & Potter, R. L. (1985) A typical neuroleptic malignant syndrome responsive to conservative treatment. Psychosomatics, 26, 62–66.Google Scholar
Mueller, P. S., Vester, J. W. & Fermaglich, J. (1983) Neuroleptic malignant syndrome. Successful treatment with bromocriptine. Journal of American Medical Association, 249, 396–398.Google Scholar
Pasternak, R. C., Braunwald, E. & Alpert, J. S. (1987) Acute myocardial infarction. In Harrison's Principles of Internal Medicine (eds Braunwald, E. et al). New York: McGraw Hill.Google Scholar
Shalev, A. & Munitz, H. (1986) The neuroleptic malignant syndrome: agent and host interactions. Acta Psychiatrica Scandinavica, 73, 337–347.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.